恒瑞医药：9款药物获临床试验批准，多产品尚无同类上市

Core Viewpoint - Heng Rui Medicine announced that the company and its subsidiaries have received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for HRS-4642 injection and eight other drugs, which will soon enter clinical trials [1] Group 1: Drug Development - HRS-4642, SHR-1701, and SHR-7367 have no similar products approved for sale domestically or internationally [1] - The remaining drugs have similar products already on the market [1] - The total research and development investment for the nine drug projects ranges from 43.1 million to 1.287 billion yuan [1] Group 2: Market Considerations - The drug development process from research to market launch is lengthy and involves multiple stages, which introduces uncertainty [1]